Core Viewpoint - The launch of the Tacrolimus extended-release capsules by Shiyao Group on JD Health represents a significant advancement in immunosuppressive therapy for organ transplant patients, offering a more convenient and stable treatment option [1][3]. Group 1: Product Launch and Features - The Tacrolimus extended-release capsules are designed to prevent transplant rejection in kidney and liver transplant patients, providing a safer and more effective immunosuppressive treatment [1]. - This new formulation allows for once-daily dosing, a shift from the traditional twice-daily regimen, which helps to stabilize drug concentration levels in the body and reduce the risk of side effects [3]. Group 2: Patient Benefits and Support - The extended-release formulation is expected to improve medication adherence and reduce patient burden, ultimately enhancing long-term treatment safety and protecting transplant kidney function [3]. - JD Health's comprehensive supply chain and online pharmacy services ensure that this specialized medication reaches patients efficiently and safely, while also offering online follow-up consultations and medication guidance [3]. Group 3: Future Plans - JD Health aims to collaborate with leading global pharmaceutical companies to introduce more innovative treatment options and provide a full spectrum of healthcare services, enhancing the quality of life for patients [4].
石药集团新药他克莫司缓释胶囊在京东健康全网首发